The Charcot-Marie-Tooth Association (CMTA), the national patient advocacy organization leading CMT research, today announced the appointment of David Coldiron to its Board of Directors.
New Gene Therapy Development Program for CMT2A
Passage Bio, a genetic medicines company developing AAV-delivered gene therapies, today announced a gene therapy development program for Charcot-Marie-Tooth Neuropathy Type 2A (CMT2A).
Frequently Asked Questions: Ionis/CMTA 1A Research Announcement
What is CMT1A? Type1ACMT1A is the most common form of
